DELTA-Q-TECHNOLOGIES
27.5.2020 22:53:13 CEST | Business Wire | Press release
Today, Delta-Q Technologies (Delta-Q) introduces its latest sealed charger with the RQ350 for electric vehicles and industrial machines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200527005918/en/
Having found significant market success with the IC Series chargers rated from 650 to 1200 watts, Delta-Q has set its sights on lower power applications with its new 350-watt charger. This new build was designed and tested to meet automotive levels of product reliability, improving machine runtimes.
“The RQ350 is a response to our customers’ needs in multiple application segments,” says Lloyd Gomm, VP of Business Development. “Our customers have asked us to bring our high reliability charger design into both lower and higher capacity battery charging applications. The RQ350 solidly answers the former need with a well thought out design offered at an OEM affordable price.”
Designed for demanding applications such as floor care machines, pallet walkies, two wheel e-mobility products, outdoor power equipment and mobile aerial work platforms, the RQ350 offers OEMs the rugged design and flexible feature set they have grown to expect and appreciate from Delta-Q’s high quality chargers. From using an IP66-sealed die cast enclosure that can tolerate harsh application environments to the integration of CAN bus, Delta-Q offers reliability and design flexibility to OEMs integrating on-board chargers. The new charger features over-voltage protection from the AC line, and is compliant to a variety of worldwide regulations such as UL, FCC B/CISPR-14 and UNECE R10.
The RQ350 also benefits from Delta-Q’s extensive library of validated charge profiles that can be specified for each charger. In addition, like the popular IC Series, charger cycle data can be downloaded, and new charging profiles can be updated by the OEM or end use customer.
RQ350 charger evaluation samples are available for OEMs to order now. Visit https://delta-q.com/rq350 .
About Delta-Q Technologies
Delta-Q Technologies, a leading provider of battery charging solutions that improve the performance and reliability of electric drive vehicles and industrial equipment, has more than 20 years of experience helping tier 1 OEMs electrify their products, while its engineering team has a combined experience of more than 60 years working with CAN programming and telematic systems. The company has become the supplier of choice to many of the world’s leading manufacturers of electric golf cars, lift trucks, aerial work platforms, motorcycles and scooters, floor care machines, and utility and recreational vehicles. Delta-Q is headquartered in Vancouver, Canada with a local presence in the U.S., Europe and Asia. For more information, please visit www.delta-q.com or follow company updates on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200527005918/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom